2014 Sales of Recombinant Therapeutic Antibodies & Proteins

  • ID: 3378007
  • Report
  • Region: Global
  • 39 Pages
  • La Merie Publishing
1 of 3
Sales Data Were Obtained From Company Publications And Refer To Branded Products Originating From Companies Based In Regulated Markets
This Competitive Intelligence report provides a compilation of the sales data of recombinant therapeutic proteins and antibodies in the calendar year 2014. Sales data were obtained from company publications and refer to branded products originating from companies based in regulated markets. All sales data were converted from their original, published currency into US$ using official currency exchange rates as of March 17, 2015. Sales figures represent the sum of revenues in all territories where the products are marketed and are mostly presented either after hedging.

Sales data are presented for each product within the respective class of biologics. The data were analyzed to establish a ranking list of blockbuster biologics with 2014 sales higher than US$ 1 bln. Another ranking list was prepared for companies according to biologics sales in 2014 and the percentage of antibody sales vs protein sales.

Note: Product cover images may vary from those shown
2 of 3
1. 2014 Biologics Sales per Class of Products

2. Blockbuster Biologics in 2014 (by generic name)

3. Company Ranking List for Biologics Sales 2014

4. Biologic Product Sales 2014
- Anti-TNF Antibodies
- Cancer Antibodies
- Insulin and Insulin Analogs
- Anti-Inflammatory and Anti-Autoimmune Antibodies
- Recombinant Coagulation Factors
- Ophthalmic Antibodies
- Erythropoietins
- Interferon beta
- Enzyme Replacement Proteins
- Human Growth Hormone
- Interferon alpha
- Follicle Stimulating Hormone
- Cardiometabolic & Anti-Infective Antibodies
- Other Proteins: Cardiometabolic, Cancer & Others

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown